Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SHBG | P04278 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548134 | 1.00 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL11097284 | 1.00 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL11874816 | 0.89 | ESR1 (0.68) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL5460095 | 0.89 | ESR1 (0.68) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL711024 | 0.89 | ESR1 (0.68) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL4749408 | 0.88 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10794417 | 0.88 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10794423 | 0.88 | ESR1 (0.67) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10792759 | 0.87 | ESR1 (0.65) | ESR1HSD17B10LMNAESR2TSHR | |
| SCHEMBL10792763 | 0.87 | ESR1 (0.65) | ESR1HSD17B10LMNAESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538100-B2 | 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | US | disclosed |
| EP-0573977-B1 | Novel estradiol derivative-chlorambucil conjugate, process for preparing the same, and pharmaceutical composition | KUREHA CHEMICAL IND CO LTD (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-5578589-A | Method for suppressing an immunoresponse with an estradiol derivative-chlorambucil conjugate | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-11-26 | — | — | US | disclosed |
| US-5576309-A | HEMATOPOIETIC OR SOLID TUMOR TREATMENT | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| US-5354745-A | Antitumor agents | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0573977-A2 | Novel estradiol derivative-chlorambucil conjugate, process for preparing the same, and pharmaceutical composition | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | ESR1 22/4885HSD17B10 39/4885LMNA 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.